Bangalore, India, October 24, 2024 – Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) has announced impressive financial results for the second quarter of FY25, showcasing significant year-on-year (YoY) growth across multiple key metrics.
Key Financial Highlights:
- Net Profit: Strides Pharma posted a net profit of ₹93.7 crore in Q2 FY25, a massive turnaround from a loss of ₹130 crore in the same period last year.
- Revenue: The company reported consolidated revenue of ₹1,201.1 crore, a 17% YoY growth compared to ₹1,026.4 crore in Q2 FY24.
- EBITDA: EBITDA surged 31% YoY to ₹235.8 crore, up from ₹180.1 crore in Q2 FY24. The EBITDA margin also improved to 19.6%, a rise of 209 basis points from the 17.5% margin last year.
- US Revenue: The company achieved a historic high of $75 million in revenue from its US business in Q2 FY25, marking a 26.2% YoY growth.
QoQ Performance:
- Revenue: On a quarter-on-quarter (QoQ) basis, revenue increased by 10.4%, rising from ₹1,087.5 crore in Q1 FY25 to ₹1,201.1 crore in Q2 FY25.
- EBITDA: QoQ, EBITDA rose by 8.7% from ₹217 crore in Q1 FY25, reflecting continued operational efficiency.
- Gross Margin: While gross margin grew by 5.4% QoQ to ₹703.2 crore, the margin percentage fell slightly to 58.5%, down by 72 basis points from the previous year.
You might also like
YoY Performance:
- Gross Margin: YoY, the gross margin grew 15.6% to ₹703.2 crore in Q2 FY25, up from ₹608.3 crore in Q2 FY24.
- EBITDA Margin: The EBITDA margin improved significantly, increasing from 17.5% in Q2 FY24 to 19.6% in Q2 FY25, representing a 209 bps improvement.
Adjusted PAT:
- Strides Pharma’s adjusted profit after tax (PAT) stood at ₹110.3 crore, a significant improvement from ₹40.5 crore in Q2 FY24.
The company’s stellar performance reflects its robust business model and growth in the US market, which continues to drive Strides Pharma’s overall profitability. With EBITDA and revenue growth on both a YoY and QoQ basis, the company has demonstrated strong operational resilience and market demand. The record-breaking US revenues further underscore the company’s strategic focus on its key growth markets.
This post was originally published on here
